SeromYx Systems is a biotechnology contract research organization selling a breakthrough type of immune profiling to pharmaceutical companies, the NIH labs, and infectious disease foundations that are developing new vaccines, immunotherapies or antibodies.
The Company’s technology platform is called Systems Serology and was developed by Dr. Galit Alter at the Harvard/MIT/MGH associated Ragon Institute. Systems Serology consists of a suite of biophysical and immune cellular assays combined with a proprietary computational algorithm that describes the antibody immune response in a powerful new way enabling the development of better vaccines, immunotherapies, and antibody products. Vaccine researchers have already used Systems Serology to design next generation vaccines with greater efficacy and to identify surrogate endpoints for biologics development, both in animal models and in human subjects. Demand for Systems Serology is increasing rapidly and SeromYx Systems is poised to provide this service to industry, academia, and government research laboratories.
SeromYx has laboratories and offices in Cambridge, MA and has hired its initial technical team. The Company expects to begin service to customers in November 2019.